Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
CONCLUSION: In patients with T2DM, saxagliptin 5 mg/d was similarly effective in improving glycemic control, with an AE profile similar to that of placebo, irrespective of CVD history, number of CV risk factors, hypertension, or statin use.
TRIAL REGISTRATION: www.ClinicalTrials.gov identifiers: NCT00327015, NCT00575588, NCT00757588.
PMID: 25414932 [PubMed - in process] (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - November 28, 2014 Category: Internal Medicine Tags: Postgrad Med Source Type: research
Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time
ConclusionsDapagliflozin improved glycaemic control, decreased body weight, and lowered blood pressure across the spectrum of T2DM disease, with maintenance of these benefits over time. (Source: International Journal of Clinical Practice)
Source: International Journal of Clinical Practice - November 28, 2014 Category: Internal Medicine Authors: S. Parikh, J. Wilding, S. Jabbour, E. Hardy Tags: Original Paper Source Type: research
A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes
Conclusion
Alogliptin demonstrated similar efficacy to glipizide in lowering HbA1c in older patients with T2DM, but with significantly more patients achieving an HbA1c ≤7.0% without hypoglycemia or an increase in body weight. These results particularly apply to patients with baseline HbA1c below 8.0%.
Funding
The study was sponsored by Takeda Global Research & Development Center, Inc., Deerfield, IL, and Takeda Global Research and Development Centre Ltd., London, United Kingdom. (Source: Diabetes Therapy)
Source: Diabetes Therapy - November 26, 2014 Category: Endocrinology Source Type: research
Interaction between Human Serum Albumin and antidiabetic compounds and its influence on the O2(1Δg)-mediated degradation of the protein
In this report, the interaction between the protein Human Serum Albumin (HSA) and two antidiabetics (Andb), Gliclazide (Gli) and Glipizide (Glip) was studied through fluorescence and docking assays, in order to characterize these systems. On the basis that HSA and Andb can be exposed in vivo at high Reactive Oxygen Species (ROS) concentrations in diabetic patients, the degradative process of the protein free and bound to Andb, in presence of the species singlet molecular oxygen (O2(1Δg)), was evaluated. Fluorescence and docking assays indicated that Gli, as well as Glip bind to HSA on two sites, with binding constants val...
Source: Journal of Photochemistry and Photobiology B: Biology - November 8, 2014 Category: Speech Therapy Source Type: research
Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective
To update the cost-effectiveness of dapagliflozin (Forxiga®), a selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor, compared with a sulphonylurea (SU) when added to metformin in patients inadequately controlled with metformin mono-therapy based on long-term clinical evidence. (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: M. Charokopou, H. Vioix, B.G. Verheggen, S. Dillon, D. Franks Source Type: research
Application Of Medicines Scoring System (Medss) : Potential Savings Through Drug Formulary Review Of Sulphonylureas
In this study we review and compare overall utility values of sulphonylureas using medicines scoring system (MedSS). (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: A Ramli, S Aljunid, S Sulong, FA Md Yusof Source Type: research
[Dapagliflozin, a novel oral antidiabetic with an uncertain future].
CONCLUSIONS: Dapagliflozin does not provide advantages over pharmacotherapy for DM2. Its lack of experience of use, the absence of significant clinical benefits and its high cost make it necessary to restrict its use.
PMID: 25542657 [PubMed - in process] (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - November 1, 2014 Category: Drugs & Pharmacology Authors: Escudero Vilaplana B, Almodóvar Carretón MJ, Herrero Hernández S Tags: Farm Hosp Source Type: research
The role of phosphoenolpyruvate carboxykinase in neuronal steroidogenesis under acute inflammation.
Abstract
Phosphoenolpyruvate carboxykinase (PEPCK) is a key gluconeogenic enzyme found in many tissues throughout the body including brain. In the present study, we have investigated the effect of bacterial lipopolysaccharide (LPS) on PEPCK and its role in neuronal steroidogenesis. Adult female albino rats were administered LPS (5mg/kg body weight) to induce acute inflammation. LPS administration resulted in a significant increase of PEPCK mRNA expression with concomitant increase in mRNA levels of steroidogenic acute regulatory (StAR) protein and other steroidogenic enzymes including 3β-hydroxysteroid de...
Source: Gene - September 22, 2014 Category: Genetics & Stem Cells Authors: Sadasivam M, Ramatchandirin B, Balakrishnan S, Selvaraj K, Prahalathan C Tags: Gene Source Type: research
Pharmacoepidemiologic and in vitro evaluation of potential drug–drug interactions of sulfonylureas with fibrates and statins
ConclusionsUse of fenofibrate or gemfibrozil together with glyburide was associated with elevated overall risks of serious hypoglycaemia. CYP inhibition seems unlikely to explain this observation. We speculate that a pharmacodynamic effect of fibrates (e.g. activate peroxisome proliferator‐activator receptor alpha) may contribute to these apparent interactions. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - August 21, 2014 Category: Drugs & Pharmacology Authors: H. Schelleman, X. Han, C. M. Brensinger, S. K. Quinney, W. B. Bilker, D. A. Flockhart, L. Li, Sean Hennessy Tags: Drug safety Source Type: research
Durability of the Efficacy and Safety of Alogliptin Compared with Glipizide in Type 2 Diabetes Mellitus: A Two‐Year Study
ConclusionsAlogliptin efficacy was sustained over two years in patients with inadequate glycemic control on metformin alone. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - August 1, 2014 Category: Endocrinology Authors: Stefano Del Prato, Riccardo Camisasca, Craig Wilson, Penny Fleck Tags: Original Article Source Type: research
Lipid Profiling Reveals Different Therapeutic Effects of Metformin and Glipizide in Patients With Type 2 Diabetes and Coronary Artery Disease.
CONCLUSIONS: Our findings revealed the differential therapeutic effects of metformin and glipizide on comprehensive lipidomics, which were comparable with their different long-term effects on cardiovascular outcomes.
PMID: 25011952 [PubMed - as supplied by publisher] (Source: Diabetes Care)
Source: Diabetes Care - July 10, 2014 Category: Endocrinology Authors: Zhang Y, Hu C, Hong J, Zeng J, Lai S, Lv A, Su Q, Dong Y, Zhou Z, Tang W, Zhao J, Cui L, Zou D, Wang D, Li H, Liu C, Wu G, Shen J, Zhu D, Wang W, Shen W, Ning G, Xu G Tags: Diabetes Care Source Type: research
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin
ConclusionsOver 2 years, compared with glipizide, dapagliflozin demonstrated greater glycaemic durability, sustained reductions in weight and systolic blood pressure and a low hypoglycaemia rate; however, genital infections and UTIs occurred more frequently. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - July 10, 2014 Category: Endocrinology Authors: M. A. Nauck, S. Del Prato, S. Durán‐García, K. Rohwedder, A. M. Langkilde, J. Sugg, S. J. Parikh Tags: ORIGINAL ARTICLE Source Type: research
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus was inadequately controlled with metformin
ConclusionsOver 2 years, compared with glipizide, dapagliflozin demonstrated greater glycaemic durability, sustained reductions in weight and SBP, and a low hypoglycaemia rate; however, genital infection and UTI rates occurred more frequently. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - June 12, 2014 Category: Endocrinology Authors: Michael A. Nauck, Stefano Del Prato, Santiago Durán‐García, Katja Rohwedder, Anna Maria Langkilde, Jennifer Sugg, Shamik J. Parikh Tags: ORIGINAL PAPER Source Type: research
Glibenclamide and cardio-metabolic risk: a systematic review
Abstract
The aim of this review is to evaluate the safety and efficacy of glibenclamide for the treatment of type 2 diabetes mellitus, in particular we evaluated glibenclamide effect on cardiovascular risk and metabolic control, and all causes of mortality. A systematic search strategy was developed to identify randomized controlled trials included in both MEDLINE and the Cochrane Register of Controlled Trials using the terms “glibenclamide”, “secretagogues”, “type 2 diabetes”, “adverse events”, “combination therapy”, “cardiovascular risk”. Participants needed to be affected by t...
Source: International Journal of Diabetes in Developing Countries - June 1, 2014 Category: Endocrinology Source Type: research
Genotoxic evaluation of two oral antidiabetic agents in the Drosophila wing spot test
In this study, two sulfonylureas—glimepiride and glipizide—commonly used in type 2 diabetes mellitus were investigated for genotoxicity in the Drosophila wing spot test. For this purpose, three-day-old transheterozygous larvae were treated with three mutagenic compounds, and the results obtained were compared with the control group. Mutational or recombinogenic changes were recorded in two recessive genes—multiple wing hairs (mwh) and flare (flr 3). Two recessive markers were located on the left arm of chromosome 3, mwh in map position 0.3, and flare-3 (flr3) at 38.8, while the centromere ...
Source: Toxicology and Industrial Health current issue - April 29, 2014 Category: Toxicology Authors: Gurbuzel, M., Capoğlu, I., Kızılet, H., Halıcı, Z., Ozcicek, F., Demirtaş, L. Tags: Articles Source Type: research
